Antibe Therapeutics (STU:4B70) FFO


STU:4B70 Antibe Therapeutics Inc STU:4B70
10 GF Score
Price €2.44
View Full Analysis

What is Antibe Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

STU:4B70
10GF Score
Antibe Therapeutics Inc STU:4B70
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Antibe Therapeutics Business Description

Address 15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2
Antibe Therapeutics Inc is a clinical stage biotechnology company leveraging its proprietary hydrogen sulfide (H2S) platform to develop next-generation therapies to address inflammation arising from a wide range of medical conditions. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Antibe's drug, otenaproxesul, is in development for the treatment of acute and chronic pain. The company's second pipeline drug is a GI-sparing alternative to ketoprofen. The company's next target is inflammatory bowel disease (IBD), a condition long in need of safer, more effective therapies.
10GF Score

Get the complete analysis for STU:4B70

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.44
Price